Vivani Medical, Inc.
VANI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.39 | -0.29 | 0.00 | 0.00 |
| FCF Yield | -6.21% | -10.60% | -8.31% | -9.17% |
| EV / EBITDA | -14.85 | -12.53 | -10.55 | -10.61 |
| Quality | ||||
| ROIC | -34.31% | -30.01% | -21.45% | -17.50% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.97 | 0.85 | 0.82 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 35.49% | -56.81% | 15.39% | -7.12% |
| Safety | ||||
| Net Debt / EBITDA | -2.33 | -1.68 | -0.92 | -0.15 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,554.71 | -885.88 | 57.21 |